<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">8611384</article-id><article-id pub-id-type="pmc">2074363</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Tallimustine in advanced previously untreated colorectal cancer, a phase II study.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Punt</surname><given-names>C. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Humblet</surname><given-names>Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Roca</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dirix</surname><given-names>L. Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wainstein</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Polli</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Corradino</surname><given-names>I.</given-names></name></contrib></contrib-group><aff>University Hospital Nijmegen, The Netherlands.</aff><pub-date pub-type="ppub"><month>3</month><year>1996</year></pub-date><volume>73</volume><issue>6</issue><fpage>803</fpage><lpage>804</lpage><abstract><p>Tallimustine is a novel benzoyl mustard derivative from distamycin A with a unique mode of action. It is a DNA minor groove binder and produces highly sequence-specific alkylations. Previous studies have shown significant anti-tumour effects in animal models. We performed a phase II study in previously untreated patients with advanced colorectal cancer, using a schedule of i.v. bolus infusions of 900 microgram m-2 once every 4 weeks. Seventeen patients were enrolled, and no responses were documented in 14 evaluable patients. Toxicity mainly consisted a highly selective neutropenia, which warrants further investigation of this agent in combination with myeloid growth factors.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00034-0093.tif" xlink:title="scanned-page" xlink:role="803" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00034-0094.tif" xlink:title="scanned-page" xlink:role="804" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

